In addition, aberrant regulations of the Rho pathway, which could take place upon fusion of ARHGAP with a RhoGAP domain to CLDN18 with transmembrane domains, may influence tumor cell movements and invasiveness. This evidence concerns the gene RHO and neoplasm.